Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (February 2025)
30 slides from Maia Biotechnology's investor presentation, Feb 5, 2025
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA February 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are “forward-looking statements." These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; sta
Slide 3: Investment Profile
INVESTMENT PROFILE NYSE American: MAIA New science for cancer therapy: dual MoA - telomere targeting and immunogenicity. * Lead molecule THIO in clinic; 2nd generation compounds in R&D Phase 2 trial THIO-101 expansion in 2025: THIO sequenced with CPI in NSCLC. * Unprecedented disease control, respon
Slide 4: Robust Pipeline
ROBUST PIPELINE THIO Telomere Targeting Agent NYSE American: MAIA ClinicalTrial Indication Treatment Status Preclinical Phase 1 Phase 2 Phase 3 Rights THIO > Planned THIO-104 NSCLC 3L CPI Phase 3 . THIO > Ongoing THIO-101 Bese Kee7 Ea Libtayo® Phase 2 Worldwide rights owned CRC, HCC, THIO > Planned
Slide 5: Mission and Approach
MISSION AND APPROACH
Slide 6: Oncology Landscape
ONCOLOGY LANDSCAPE Population aged >80 ' [i = expected to triple by 2050 e) Cancer is the 142 At age 90 H oe age : ee erelated j HUE 40% will be diagnosed \ oF cacti citi welt an disease 426 20% will die of it million -a emu, 2050
Slide 7: Novel Treatment
NOVEL TREATMENT THIO is the only direct telomere targeting anticancer agent in clinical development
Slide 8: THIO - Novel Mechanism of Action
THIO - NOVEL MECHANISM OF ACTION NYSE American: MAIA THIO Followed by (6-thio-2'-deoxyguanosine) Immune Checkpoint Inhibitor (CPI) THIO has a dual Mechanism of Action: * Examples of commercially available CPIs: @ Telomere targeting Y} TEVIMBRA death (2) Immunogenic effect (cemiplimab) (tislelizumab)
Slide 9: THIO-101 NSCLC Trial - Rationale
THIO-101 NSCLC TRIAL - RATIONALE 1000 * THIO followed by CPI results in 60% 900) complete response 800 * Only 2 cycles of therapy were = 700 administered on weeks 1 and 2; no = 600 further therapy throughout the study — 2 500 * No recurrence after long-term follow-up $ ‘00 i=] * Anticancer immune me
Slide 10: NSCLC Clinical Trials
NSCLC CLINICAL TRIALS
Slide 11: THIO-101 Phase 2 Trial Design with Libtayo in NSCLC
A Multicenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Safety Efficacy/Safety/Dose Selection THIO 60mg + Libtayo® o (n=24) ; THIO + ¢ | _ Libtayo
Slide 12: THIO-104 Phase 3 Pivotal Trial Design (Planned)
THIO-104 PHASE 3 PIVOTAL TRIAL DESIGN (PLANNED) NYSE American: MAIA A Multicenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of THIO Administered in Sequence with a Checkpoint Inhibitor in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Compared to Chemotherapy pT NSCLOSL_—
Slide 13: Best Results in Third-Line with the 180mg Dose
BEST RESULTS IN THIRD-LINE WITH THE 180MG DOSE NYSE American: MAIA THIO-101 (Pivotal Phase 2, ongoing): Overall Survival (3L) * Current data in third-line indicates that as of 15-Jan-2024, 1.00] — estimated Median Overall Survival (OS) is at 16.9 months __ with a 95% CI lower bound of 12.5 months an
Slide 14: Expected Efficacy in Pivotal Trials in NSCLC 3L
EXPECTED EFFICACY IN PIVOTAL TRIALS IN NSCLC 3L Target Population DCR ORR PFS Os THIO-1014 Pivotal Phase 2 THIO + Libtayo® (n = 137-148) * CPI + Platinum Resistant THIO-104 Pivotal THIO + CPI (n = 150) * CPI + Platinum Resistant (6) MAIA NYSE American: MAIA Phase 3 Chemotherapy (n = 150) median foll
Slide 15: Other Tumor Types Planned Trials
OTHER TUMOR TYPES PLANNED TRIALS
Slide 16: THIO-102 Trial (Planned)
THIO-102 TRIAL (PLANNED) NYSE American: MAIA A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with a Checkpoint Inhibitor (CPI) Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 2 Umbrella Arms Colorectal Cancer (C Hepatocellul . we Ex
Slide 17: Colorectal Rationale
COLORECTAL RATIONALE NYSE American: MAIA 700 ==Control z 600 —eAtezolizumab £ 500 * THIO followed by CPI results in 100% 2 400 ele complete response 2 500 STD Panes > * Only 2 cycles of therapy were S 200 i E administered on weeks 1 and 2; no E 100 eee CR further therapy throughout the study 0 * No
Slide 18: SCLC & HCC - Orphan Drug Designation
SCLC & HCC —- ORPHAN DRUG DESIGNATION SCLC 1500 =—eControl Rp N a o —e=Pembro > THIO —e—THIO > Pembro Tumor Volume (mm?} ~J] 3 0 5 10 15 20 25 Days After Tumor Inoculation THIO is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2081) in vive in humanized murine cancer m
Slide 19: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS (6) MAIA NYSE American: MAIA Hcc 6005|- Control << THIO * THIO achieved complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models Tumor Volume (mm?) N So o 0 5 1015202530354045 Days after
Slide 20: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY * When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated * Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented * Administration of THIO alone and in co
Slide 21: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with a Checkpoint Inhibitor (CPI) Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 3 SCLC First Line THIO | : CPIs: Expand to Activation -—> * Opportunity to te
Slide 22: Investment Opportunity
INVESTMENT OPPORTUNITY
Slide 23: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY "4'4 NYSE American: MAIA Goal: New Chemical Entity (NCE) Marketing Exclusivity A * THIO has never been previously approved by the FDA for commercialization * Robust exclusivity ¢ US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio
Slide 24: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM NYSE American: MAIA % Vlad Vitoc, MD, MBA Sergei Gryaznov,PhD Jeffrey Himmelreich, MBA Founder and CEO Chief Scientific Officer Head of Finance * 24+ years in Oncology Pharma/ °¢ 25+ years as Scientist * 20+ years of financial Biotech: Commercial, Medical + Expert Drug Di
Slide 25: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY (bw) MAIA Developing agents for the top tumor ; types markets globally NSCLC (#4 WW) Hcc Mortality: 1.7M / Sales: $34B Mortality: 0.8M / Sales: $3B CRC 2 WW) scLe Mortality: 1.0M / Sales: $20B Mortality: 0.3M / Sales: $2B $46B CPIs Group (2023 Sales) Ss * § CPIs approv
Slide 26: Comparable Companies
COMPARABLE COMPANIES (6) MAIA NYSE American: MAIA ° On June 3, 2022, Bristol Myers Squibb (BMS) announced the acquisition of Turning Point Therapeutics in an all-cash transaction for $4.1B in equity value value right ° Commercial stage companies: Mirati (on acquisition) On October 9, 2023, BMS acqui
Slide 27: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES NYSE American: MAIA THIO-104 Enrollment Potential Early Full Approval Ph3 First Patient In in US (from interim analysis) NSCLC 3L * THIO-401 Part c Part B Part Cc Enrollment Filing for Potential Ph2 First Full Efficacy Complete US Accelerated Patient In Efficacy Upd
Slide 28: Thank You
NYSE American: MAIA MAIA BIOTECHNOLOGY THANK YOU Investor Relations Contact +1 (872 90-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 70, IL 60606 28
Slide 29: Appendix
APPENDIX
Slide 30: U.S. FDA Granted Orphan Drug Designations and Rare Pediatric Disease Designation to THIO
U.S. FDA GRANTED 3 ORPHAN DRUG DESIGNATIONS AND 1 MAIA RARE PEDIATRIC DISEASE DESIGNATION TO THIO eee V} THIO has been granted 3 Orphan Drug Designations (ODD): ¥ Hepatocellular Carcinoma (HCC, 90% of primary liver cancers) ¥ Small Cell Lung Cancer (SCLC, deadliest lung cancer) ¥ Glioblastoma (brain
MAIA Biotechnology — Investor Presentation (February 2025) on 6ix